spacer
home > ebr > spring 2019 > jewel biomarkers can be found by digging in the right mine
PUBLICATIONS
European Biopharmaceutical Review

Jewel Biomarkers Can Be Found By Digging in the Right Mine

Biomarkers can be fantastic diagnostic tools, especially for rare diseases (1:2,000 up to about 1:100,000) for which an accurate identification may even be lifesaving if identified early on. Literature and experts see biomarkers as cornerstones for the development of new therapeutic approaches.

The EMA and FDA are proponents of seeing the therapeutic effects achieved through biomarker-based ‘theragnostic’. Historically, surrogate biomarkers were accepted in the past (for example, haemoglobin A1c for diabetes). Nowadays, however, biomarkers closely linked to a sickness and potential therapeutic intervention are even more welcome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Hermann Mascher, Bioanalytical Consultant and founder of pharm-analyt Labor, has more than 100 publications in peer-reviewed journals (and more than 230 cumulative impact factor). He is the inventor of three patents for biomarkers in the area of rare LSDs (Gaucher, NP-C, and metachromatic leukodystrophy) which could be sold.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Labguru integrates free video conferencing & documenting tool to support remote lab collaboration during COVID-19

2 April 2020, Cambridge MA – Electronic laboratory notebook (ELN) pioneer, BioData, today announces its support for the global science community with the introduction of a new video conferencing service in its leading Labguru ELN platform, free of charge for all customers.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement